Brief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
BRIEF-Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma Nov 11 (Reuters) - Oncolytics Biotech Inc ONCY.O:
ONCOLYTICS BIOTECH® ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE PELAREOREP IN COMBINATION WITH LOQTORZI® (TORIPALIMAB-TPZI) IN SQUAMOUS CELL ANAL CARCINOMA
ONCOLYTICS BIOTECH - STUDY EXPECTED TO BEGIN IN THE U.S. IN Q1 2027
Source text: ID:nGNX5hymWH
Further company coverage: ONCY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer